Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

Ligand Pharmaceuticals (Nasdaq: LGND) announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026, followed by a conference call at 8:30 a.m. Eastern time to discuss results and provide a general business update.

Rhea-AI Summary

Ligand Pharmaceuticals (Nasdaq: LGND) announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026, followed by a conference call at 8:30 a.m. Eastern time to discuss results and provide a general business update.

The call offers U.S. local and toll-free dial-in options, international access via global dial-in numbers using Meeting ID 780702347, and a live and replay webcast. Ligand describes itself as a royalty aggregator with economic interests in more than 200 development and commercial-stage biopharmaceutical assets and also licenses its Captisol and NITRICIL technologies.

Argus Jul 23 session

-0.69% close to close Open Argus

Details

News Market Reaction – LGND

In the Jul 23 session, LGND declined 0.69%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

LGND's earnings-date history recorded -0.06% and -2.32% reactions. That platform record places this ...

Analysis

LGND's earnings-date history recorded -0.06% and -2.32% reactions. That platform record places this scheduling notice alongside prior pre-results announcements; recent insider data showed Net Selling, while the August 6 report remains the key watchpoint.

Key Figures

Reporting period: Second quarter 2026 Results date: August 6, 2026 Conference call time: 8:30 a.m. Eastern time +1 more

Reporting period

Second quarter 2026

Scheduled financial results

Results date

August 6, 2026

Second-quarter 2026 results

Conference call time

8:30 a.m. Eastern time

Results discussion and business update

Royalty assets

More than 200 assets

Company description

Previous Earnings date Reports

2 past events · Latest: Apr 22

Same Type 2 events

1. Apr 22

   earnings date

   24h Move

   -0.1%

   Scheduled first-quarter 2026 results and an 8:30 a.m. conference call.

2. Feb 12

   earnings date

   24h Move

   -2.3%

   Scheduled fourth-quarter and full-year 2025 results with an 8:30 a.m. call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

royalty aggregator, late-stage clinical development programs

2 terms

royalty aggregator financial

"Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies"

A royalty aggregator is a company or fund that buys and manages many royalty or revenue-sharing rights across industries, such as music, pharmaceuticals, natural resources, or intellectual property. Like a person buying a collection of toll booths instead of running a highway, it pools small, ongoing payments from many sources into a single portfolio, creating diversified, often predictable cash flows that investors can track and value.

late-stage clinical development programs medical

"partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs"

Programs composed of the final, large-scale clinical trials and supporting studies that test a drug or medical device’s safety, effectiveness, dosing, and manufacturing before regulatory approval. These are the decisive “final road tests” for a treatment, often including pivotal Phase IIb/III studies and activities needed for filings. Results and timelines from late-stage programs strongly influence a developer’s chances of approval and the timing of potential commercial value, which is why they matter to investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update.

Conference Call and Webcast Information
Date:	Thursday, August 6, 2026
Time:	8:30 a.m. Eastern time
Conference Call:	United States (Local): +1 (585) 542-9983
	United States (Toll-Free): +1 (833) 461-5787
	International: Global Dial-in Numbers
	Meeting ID: 780702347
Webcast:	Live and replay webcasts of the call are available here.

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ligand (Nasdaq: LGND) report its second quarter 2026 earnings?

Ligand plans to report its second quarter 2026 financial results on Thursday, August 6, 2026. According to Ligand, the release will be accompanied by a conference call and webcast discussing the results and providing a general business update for investors and analysts.

What time is Ligand's Q2 2026 earnings conference call on August 6, 2026?

Ligand’s Q2 2026 earnings conference call starts at 8:30 a.m. Eastern time on August 6, 2026. According to Ligand, the call will review quarterly financial results and include a general business update accessible by phone and webcast.

How can investors access the Ligand (LGND) Q2 2026 earnings call and webcast?

Investors can join by phone using U.S. local +1 (585) 542-9983, U.S. toll-free +1 (833) 461-5787, or international global dial-in numbers with Meeting ID 780702347. According to Ligand, a live and replay webcast will also be available online.

What is the Meeting ID for Ligand's August 6, 2026 Q2 2026 earnings call?

The Meeting ID for Ligand’s second quarter 2026 earnings conference call is 780702347. According to Ligand, participants can use this ID when dialing in via global international numbers to access the call and follow the company’s financial discussion.

What type of business does Ligand (LGND) describe ahead of its Q2 2026 results?

Ligand describes itself as a royalty aggregator focused on financing late-stage biopharmaceutical programs. According to Ligand, it holds economic interests in over 200 development and commercial-stage assets and licenses proprietary technologies Captisol and NITRICIL to partners worldwide.

Will a replay of Ligand's August 6, 2026 Q2 2026 earnings webcast be available?

Yes, Ligand states that both a live and replay webcast of the August 6, 2026 Q2 2026 earnings call will be available. According to Ligand, investors can access the replay online after the event for additional review.